Novo Nordisk announces the continued supply of Mixtard, India's top-selling insulin brand, in vials, while phasing out other formats. The move is part of a global strategy to focus...
Novo Nordisk shares fell 8% after Eli Lilly reported positive trial results for its weight loss drug, orforglipron, affecting the healthcare sector. Novo Nordisk's shares dropped t...
Novo Nordisk shares fell 8% after Eli Lilly revealed positive trial results for its weight loss drug orforglipron, impacting the healthcare sector. Eli Lilly's shares saw a slight ...
Novo Nordisk shares fell 8% after Eli Lilly announced positive trial results for its weight loss drug orforglipron, impacting the healthcare sector. Eli Lilly's stock rose slightly...
Novo Nordisk shares fell 8% after Eli Lilly announced positive trial results for its weight loss drug, orforglipron, impacting the healthcare sector. Novo Nordisk's shares dropped ...
Novo Nordisk shares fell 8% after Eli Lilly announced positive results from a late-stage trial of its oral weight loss drug, orforglipron, impacting the healthcare sector broadly.
Novo Nordisk shares fell 8% after Eli Lilly announced positive late-stage trial results for its oral weight loss drug, orforglipron, impacting the healthcare sector and Novo Nordis...
Novo Nordisk's stock dropped 18% after a phase three trial for its CagriSema weight loss drug yielded results below expectations. The drug, combining semaglutide and Cagrilintide, ...
Novo Nordisk plans to invest $1.23 billion in a new Danish facility to support rare disease treatments, creating jobs and reinforcing its commitment to innovation and Danish roots.
Novo Nordisk's shares dropped over 2% after a preprint study linked Ozempic to a rare vision condition. The study, by scholars from Norway and Denmark, found Ozempic users were twi...
